MAP Pharmaceuticals Sets IPO Pricing
Mountain View-based MAP Pharmaceuticals, a biopharmaceuticals firm developing treatments for pediatric asthma and migraines, has set pricing for its IPO. In a filing with the SEC, the firm said that it will offer 5 million shares of its common stock in at between $14.00 and $16.00 per share. MAP Pharmaceuticals IPO is being underwritten by Merrill Lynch & Co., Morgan Stanley, and Deutsche Bank Securities; the firm will trade on the Nasdaq Global Market under the symbol "MAPP."
posted on Friday, September 21, 2007
Related companies:
Map My Customers, Inc.
Related stories:
> Third Rock Ventures Raises $426M Fund, Sets Up Shop In San Francisco
> Ooma Sets IPO Pricing Range
> Facebook Sets IPO Pricing Range
> Corvus Pharmaceuticals Debuts In IPO
> Pure Storage Sets IPO Pricing Range
silicontap.com Home